¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023)(4ÀÏÂ÷) : 2023-05-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023)(4ÀÏÂ÷) : 2023-05-20
±³À°ÀÏÀÚ : 2023-05-20
±³À°Àå¼Ò : ÄÚ¿¢½º

±³À°ÁÖÁ¦ : 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023)(4ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630  

À̸ÞÀÏ : webmaster@rheum.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, Áø´Ü°Ë»çÀÇÇаú, °¡Á¤ÀÇÇаú

Âü¼®¿¹»óÀÎ : 1600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 30 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 300,000¿ø  

ºñ°í »çÀüµî·Ï: Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø, ÀüÀÓÀÇ 300,000¿ø / Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø 160,000¿øÇöÀåµî·Ï: Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø, ÀüÀÓÀÇ 360,000¿ø / Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø 200,000¿ø

±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 101+102 08:00~08:40 Evolution of therapeutic B cell depletion in lupus Stephen Oliver(Novartis AG)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 08:00~08:40 Building Strong Bones for Life: Strategies for Long-Term Osteoporosis Treatment ½Å±âö(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 08:00~08:40 What is The role of IL-17A in modulating pain in patients with axial spondyloarthritis? õÀ±È«(°æ»ó´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 08:00~08:40 Selective Immunoproteasome Inhibition with Zetomipzomib for the treatment of Lupus Nephritis: Review of the Open-label mission Study Results Richard Furie(Northwell Health)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103+104+105 09:00~09:50 Synthetic biology and next-generation biomedicine Á¶º´°ü(Ä«À̽ºÆ®)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 101 09:15~09:45 Musculoskeletal diseases in systemic lupus erythematosus Chak-Sing Lau(Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 102 09:15~09:45 Lupus nephritis Tak Mao Chan(Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205A+B 09:15~09:45 Pulmonary hypertension Mandana Nikpour(The Univ. of Melbourne at St. Vincent)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 10:30~11:00 Diagnostic challenges in systemic lupus erythematosus David Isenberg(Univ. College London)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 11:00~11:30 Challenges in measuring clinical outcomes in systemic lupus erythematosus Eric Morand(Monash Univ.)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 11:30~11:40 Working towards a core minimal dataset for systemic lupus erythematosus studies Ian Bruce(The Univ. of Manchester)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 11:40~11:50 Increased IFITM gene-signatures in age-associated B and plasma cells define non-response to mycophenolate mofetil in systemic lupus erythematosus Daniel Toro-domínguez(GENYO. Centre for Genomics and Oncological Research: Pfizer, Univ. of Granada)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 11:50~12:00 Towards a novel clinical outcome assessment for systemic lupus erythematosus trials - first outcomes of an international consensus process Eric Morand(Monash Univ.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 10:30~11:00 Fibromyalgia, how stress becomes neuropathic pain Manuel Martinez-Lavin(Nat'l Institute of Cardiology)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 11:00~11:30 What role for neuroinflammation and small fiber neuropathy in fibromyalgia? ¿ÀÁö¿µ(°Ç±¹´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 11:30~12:00 New insights into the pathophysiology of fibromyalgia ȲÁö¿ø(¼º±Õ°ü´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 10:30~10:40 A novel therapeutic target for arthritis pain Kevin Lee(Univ. of Melbourne)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 10:40~10:50 AMP-activated protein kinase modulates the migration of fibroblast-like synoviocytes via SLC7A11-NOX4-ROS signaling in patients with rheumatoid arthritis ÀÌÇϸ§(Ãæ³²´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 10:50~11:00 Exosome-based delivery of super-repressor I¥êB ameliorates inflammation in Rheumatoid Arthritis ÀÌÇØÀÎ(Àü³²´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 11:00~11:10 Low-dose radiotherapy attenuates experimental autoimmune arthritis by inducing lymphocyte apoptosis ±èº¸±Ô(°æ»ó´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 11:10~11:20 Identification of three novel susceptibility loci for rheumatoid arthritis in a large-scale genome-wide association study in the Korean population ±Ç¾Æ¿µ(°æÈñ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 11:20~11:30 The effect of treatment with TIP-1 and MIP-2 through blocking TLRs in adult-onset Still ¾È¹ÌÇö(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 11:30~11:40 Multi-tissue adaptive regeneration of musculoskeletal tissues by novel human musculoskeletal stem cells induced from hPSCs ÀÌ»óÀÏ(°æ»ó´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 10:30~10:40 Use of Infliximab in 90 children with Kawasaki Disease: Experience from a tertiary care centre in North-West India Prabal Barman(Post Graduate Institute of Medical Education and Research)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 10:40~10:50 A comparative study of pattern of paediatric uveitis in different subtypes of juvenile idiopathic arthritis: Experience from a tertiary care centre in North-West India Prabal Barman(Post Graduate Institute of Medical Education and Research)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 10:50~11:00 Educational Project for Rheumatology through a self-paced online learning platform: 6 year update of Applied Rheumatology on the Go Lisa Traboco(St Luke's Medical Center, Univ. of the Philippines)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 11:00~11:10 Prediction of osteoporosis in patients with rheumatoid arthritis using machine learning ÀÌä¿ø(°­¿ø´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 11:10~11:20 Artificial intelligence for detection of inflammatory sacroiliitis in magnetic resonance imaging in patients with axial spondyloarthritis À̽½±â(¼º±Õ°ü´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 11:20~11:30 Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: A case-control study ±èÁÖ¿¬(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 11:30~11:40 Germanium Telluride-Polyvinylpyrrolidone Nanosheets ameliorate inflammatory response in inflammatory disease model ÇÑÁöÀº(¿¬¼¼´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 101+102 12:00~12:40 Identification of risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus & updates of 2022 European Society of Cardiology / European Respiratory Society pulmonary hypertension Guidelines ÀÌ¿¬¾Æ(°æÈñ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 12:00~12:40 Review the clinical trial data for XELJANZ across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis Uta Kiltz(Rheumazentrum Ruhrgebiet)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 12:00~12:40 CT-P17(Yuflyma) clinical trial review based on efficacy and safety ±èÇö¾Æ(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 12:00~12:40 Practical approach of Mucosta slow release in rheumatology: Optimal gastrointestinal medication & additional benefit ±èÇö¼÷(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 13:00~13:20 The skin manifestation of lupus: From genotype to phenotype Yong Cui(China-Japan Friendship Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 13:20~13:40 Systemic lupus erythematosus-pulmonary arterial hypertension: The way to reach the dual target Mengtao Li(Peking Union Medical College Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 13:40~14:00 Decoding neurocognitive dysfunction in systemic lupus erythematosus with advanced functional neuroimaging Anselm Mak(Nat'l Univ. of Singapore)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 14:00~14:10 Performance of combining eye sign and functional magnetic resonance imaging in diagnosing patients with neuropsychiatric systemic lupus erythematosus Jenny Lin-Hong Shi(The Chinese Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 14:10~14:20 The effects and molecular mechanisms of TRAF5 on pulmonary artery endothelial cells in patients with systemic lupus erythematosus associated pulmonary arterial hypertension Xiaoyue Deng(Peking Union Medical College Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 14:20~14:30 Inhibition of transcolbalamin2 overexpression ameliorated renal injury in systemic lupus erythema via reducing pathogenic Tfh and B cell infiltration Baoyi Liu(China-Japan Friendship Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 101 13:00~13:20 Myeloid-derived suppressor cells in systemic lupus erythematosus °û½Â±â(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 101 13:20~13:40 Effector B cell responses in systemic lupus erythematosus Ignacio Sanz(Emory Univ.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 101 13:40~14:00 Role neutrophils in systemic lupus erythematosus pathogenesis Mariana Kaplan(Nat'l Institute of Arthritis and Musculoskeletal and Skin Diseases)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 101 14:00~14:10 ETV5 promotes follicular helper T cell differentiation and lupus pathogenesis ¹ÚÁöÈ£(POSTECH)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 101 14:10~14:20 Vitamin D3 mitigates immune system alterations caused by activation of myeloid dendritic cells in SLE Mingfang Li(The Third Affiliated Hosp. of Guangzhou Medical Univ.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 101 14:20~14:30 Altered peripheral non-classic monocyte and NKT counts and CD8+ TCR diversity of systemic lupus erythematosus identified via integrated high-dimensional flow cytometry, CyTOF, metabolic profiling and TCR clonality analyses Anselm Mak(Nat'l Univ. of Singapore)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 102 13:00~13:20 Antiphospholipid syndrome: 40 years on and counting! Munther Khamashta(Kings College London)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 102 13:20~13:40 Management of obstetric antiphospholipid syndrome Michelle Petri(Johns Hopkins Univ.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 102 13:40~14:00 Catastrophic antiphospholipid syndrome Nathalie Costedoat-Chalumeau(Cochin Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 102 14:00~14:10 The efficacy of tacrolimus in antiphospholipid antibodies associated thrombocytopenia: A prospective cohort study Yu Shi(Peking Union Medical College)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 102 14:10~14:20 Severe thrombocytopenia is associated with adverse pregnancy outcomes in obstetric antiphospholipid syndrome Jiayang Jin(Peking Univ. People)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 13:00~13:30 The role of metabolism in the pathogenesis of osteoarthritis Ali Mobasheri(Univ. of Oulu)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 13:30~14:00 Chondrocyte metabolisms, reactive oxygen species and inflammation Çѽ¿ì(°æºÏ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 14:00~14:10 Enhancing oxidative phosphorylation through inhibition of PDK2 alleviates cartilage degradation in a surgical model of osteoarthritis ÇÑÁø(°æºÏ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 14:10~14:20 Genetic knockout of CXCR7 in articular chondrocyte has potential protective effect on advanced knee osteoarthritis in mouse model ¹ÚÁØ¿ë(µ¿¾Æ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 14:20~14:30 Effect of intra-articular injection of stigmasterol loaded nanoparticles in osteoarthritis rat model Á¤ÀçÇö(°í·Á´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 13:00~13:10 COVID-19 Infection in patients with rheumatic disease during Omicron outbreak in South Korea: A single-center prospective study ±èÀ±±Ô(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 13:10~13:20 Effects of COVID-19 and influenza vaccination on rheumatic diseases: Results from a survey of patient-reported outcome after vaccination ±èÁö¿ø(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 13:20~13:30 Immune response and safety of COVID-19 vaccine in patients with autoimmune diseases Pichaya O-charoen(Mahidol Univ.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 13:30~13:40 Dynamic immune features revealed by single-cell RNA and single-cell TCR/BCR sequencing in patients with rheumatoid arthritis receiving SARS-CoV-2 booster vaccination Yong Fan(Peking Univ. First Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 13:40~13:50 Modeling of antibody response to COVID-19 vaccinations in patients with rheumatoid arthritis ±èÀ±±Ô(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 13:50~14:00 Flares in IIMs and the timeline following COVID-19 Vaccination: A combined analysis of the COVAD-1 and 2 surveys Latika Gupta(Univ. of Manchester)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 14:00~14:10 Immunologic response and effects of COVID-19 vaccines in patients with ANCA-associated vasculitis µµÇö¼ö(¿¬¼¼´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 13:00~13:10 Longitudinal analysis and treatment response of pathogenic B cells in Sjögren¡¯s syndrome Joanne Reed(Westmead Institute for Medical Research)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 13:10~13:20 Binding of CXCL13 with heparan sulfate of syndecan-1 plays an important role in pathogenesis of Sjögren¡¯s syndrome ÀåÁö¾Ö(´ë±¸ÆÄƼ¸¶º´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 13:20~13:30 Kynurenine pathway can be a potential biomarker of fatigue in primary Sjögren¡¯s syndrome ¹Ú¿µÀç(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 13:30~13:40 High dimensional cartography of lymphocytes using single-cell mass cytometry differentiates systemic lupus erythematosus and primary Sjögren`s syndrome Franziska Szelinski(Charité)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 13:40~13:50 Risk of incident psoriasis in patients with systemic sclerosis: a nationwide cohort study ±Ç¿ÀÂù(¿¬¼¼´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 13:50~14:00 All-cause mortality and risk factors for death in a large multi-center prospective registry cohort of idiopathic inflammatory myositis in China Liying Peng(Peking Union Medical College Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 14:00~14:10 Serial imaging changes in skeletal muscle composition and their association with clinical outcomes in idiopathic inflammatory myopathies (IIM) Mamatha Gorijavolu(Jawaharlal Institute of Postgraduate Medical Education and Research)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 14:10~14:20 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy °­Çظ²(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 206A+B 14:30~14:35 CHA2DS2-VASc score for prediction of ischemic stroke in patients with systemic lupus erythematosus without atrial fibrillation-RISK of risk scores in the era of artificial intelligence Wei Syun Hu(China Medical Univ. Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 206A+B 14:35~14:40 Correlation of traditional and SLE related risk factors with carotid intima media thickness as early MACEs predictor in SLE patients : A systematic review and meta-analysis Sandra Surya Rini(North Lombok Regional Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 206A+B 14:40~14:45 Improvements and challenges of systemic lupus erythematosus associated pulmonary arterial hypertension£º A 10-year multicenter cohort study Xingbei Dong(Peking Union Medical College Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 206A+B 14:45~14:50 All-cause mortality and the incidence of cancer in patients with moderate-to-severe SLE: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR) Ian Bruce(The Univ. of Manchester)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 206A+B 14:50~14:55 Performance of conventional cardiovascular risk scores in identifying subclinical atherosclerosis in Systemic Lupus Erythematosus Gayathri Ms(Jawaharlal Institute of Postgraduate Medical Education and Research)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 206A+B 14:55~15:00 Risk factors associated with the development of cardiovascular events in a multiethnic Asian systemic lupus erythematosus cohort Hwee Siew Howe(Tan Tock Seng Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 206A+B 15:00~15:05 Association of hypertension with higher chronicity index scores among patients with lupus nephritis Peter Paolo Daleon(Univ. of Santo Tomas Hosp.)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:30~14:35 Understanding the genetic architecture of SLE from the perspective of associations from 14 other autoimmune diseases Wanling Yang(Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:35~14:40 Identification of an interferon 5-gene signature score as a pharmacodynamic and potential predictive biomarker for deucravacitinib treatment in a phase 2 trial in patients with systemic lupus erythematosus Chun Wu(Bristol Myers Squibb)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:40~14:45 Clinical characteristics and genetic variants in a large cohort of monogenic lupus patients: emerging or fading frontiers? Sulaiman Al-mayouf(King Faisal Specialist Hosp. & Research Center)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:45~14:50 Dynamic changes of immune cells in systemic lupus erythematosus with nephritis using longitudinal peripheral blood single-cell RNA-seq ¹é½ÂÁØ(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:50~14:55 Machine-learning approach on lupus low disease activity prediction Nick Faelnar(Univ. of the Philippines)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:55~15:00 Genomic Prediction model using Machine Learning Techniques that can distinguish Autoimmune Diseases (RA or SLE) from Healthy Controls Young Bin Joo(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205A 14:30~14:35 ¡°Systemic lupus erythematosus Women with lupus nephritis In pregnancy Therapeutic CHallenge (SWITCH)¡±: The Systemic Lupus International Collaborating Clinics Experience Joo-Young (Esther) Lee(Research Institute of McGill Univ. Health Centre)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205A 14:35~14:40 Pregnancy outcomes in patients with systemic lupus erythematosus (SLE) , anti-phospholipid antibody syndrome (APL) , scleroderma (SSc) and Rheumatoid arthritis (RA) at the Kenyatta national hospital, Nairobi, Kenya. Paul Etau Ekwom(KNH)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205A 14:40~14:45 Nationwide patterns and factors associated with adverse pregnancy outcomes in women with Systemic Lupus Erythematosus Á¤À¯¼±(Áß¾Ó´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205A 14:45~14:50 Pregnancy outcomes in systemic lupus erythematosus: Data from a Multiethnic, multinational Latin American cohort Guillermo Pons-estel(Centro Regional de Enfermedades Autoinmunes y Reumáticas)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205B 14:30~14:35 Sub-optimal use of anti-malarial therapy for SLE in The Asia Pacific Region; Observations From The Asia Pacific lupus cohort Rangi Kandane-rathnayake(Monash Univ.)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205B 14:35~14:40 Ld-IL2 synthesis with Belimumab in the treatment of Systemic Lupus Erythematosus patients Ruiling Feng(Peking Univ. People)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205B 14:40~14:45 Effectiveness of belimumab in systemic lupus erythematosus patients of a multicenter Spanish cohort. Irene Altabás-gonzález(Complejo Hospitalario universitario de Vigo)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205B 14:45~14:50 A placebo-controlled phase 1 study in healthy adult volunteers of the safety, tolerability, pharmacokinetics, and pharmacodynamics of povetacicept, a potent dual BAFF/APRIL antagonist, for the treatment of systemic lupus erythematosus Stacey Dillon(Alpine Immune Sciences)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205B 14:50~14:55 Study design of ENERGY: A phase 2/3 trial to assess the efficacy and safety of nipocalimab in warm autoimmune hemolytic anemia ÀÌ¿µÀÚ(Janssen Asia Pacific)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 205B 14:55~15:00 Safety, efficacy and pharmacodynamics of cenerimod in patients with systemic lupus erythematosus: Two randomised, double-blind phase 2 clinical trials Sandra V Navarra(Univ. of Santo Tomas)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:30~14:35 Gut microbiota analysis in Korean patients with Systemic Lupus Erythematosus ±èÁö¿ø(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:35~14:40 Analysis of microbiota in patients with systemic lupus erythematosus Toshihiro Nanki(Toho Univ. School of Medicine)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:40~14:45 Analyzing the shared and specific genetic signals among 15 autoimmune diseases shed new light on the underlying causal genes and molecular mechanisms Xiao Dang(The Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:45~14:50 Captopril preventing blood brain barrier breach by Anti-Smith Antibody Yoshiyuki Arinuma(Kitasato Univ. School of Medicine)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:50~14:55 Ambulatory blood pressure in patients with systemic lupus erythematosus Brygida Przywara-chowaniec(Medical Univ. of Silesia)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:55~15:00 Characteristics associated with poor COVID-19 outcomes in people with rheumatic disease: data from one single center from China Haihong Yao(Peking Univ. People)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 15:00~15:05 Comparison of COVID-19 vaccination with Influenza vaccination in Korean patients with systemic lupus erythematosus: perception, adverse events, and flares from the CIVIL study ¹Ú¼ºÈÆ(´ë±¸°¡Å縯´ëÇб³)

Åä·Ð 05¿ù 20ÀÏ ÄÁÆÛ·±½º·ë 209A 14:30~15:30 Meet the Mentor 4 ±è¼ºÀ±(±è¼ºÀ±³»°ú)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 15:30~16:00 Systemic Lupus Erythematosus: Basic research ½É½Âö(Ãæ³²´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ¿ÀµðÅ丮¿ò 16:00~16:30 Systemic Lupus Erythematosus: Clinical research ¹Ú¼ºÈ¯(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 15:30~16:00 Assessment in Spondyloarthritis International Society health index and spondyloarthritis treatment Uta Kiltz(Rheumazentrum Ruhrgebiet)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 16:00~16:30 The epidemiology and treatment of ankylosing spondylitis in Korea ±Ç¼º·Ä(ÀÎÇÏ´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 16:30~16:40 Time-dependent csDMARDs use and inflammatory burden can predict cardiovascular risk in patients with ankylosing spondylitis: A population-based study Jenny Lin-Hong Shi(The Chinese Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 103 16:40~16:50 Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis ±èÁö¿ø(´ë±¸°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 15:30~16:00 How to write effective peer review comments ȲÀ±Èñ(Compecs Inc.)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 16:00~16:30 Creating effective scientific figures for publication °­ÇöÁÖ(¸Þµå¾ÆÆ®)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 104 16:30~17:00 Appropriateness of study design in biomedical journal ±èâ¼ö(¿¬¼¼´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 15:30~16:00 Functional responsibility of insurance and policy committee ±èºÀ¼®(º¸·ÉÁ¦¾à)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 16:00~16:30 Practical tips from health insurance review & assessment service °íÀº¹Ì(¼º±Õ°ü´ëÇб³)

±³À°½Ã°£ 05¿ù 20ÀÏ ±×·£µåº¼·ë 105 16:30~17:00 Rheumatic diseases and Korean version of International Classification of Diseases (ICD)-11 À±º¸¿µ(ÀÎÁ¦´ëÇб³)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °æ±âµµÀÇ»çȸ Á¦9Â÷ ½Å±Ô°³¼³ÀÇ·á±â°ü ¼¼¹Ì³ª : 2023-05-20
´ÙÀ½±Û Á¦7ȸ µ¿³²±Ç´ëÀåÇ×¹®Æ÷·³ (1ÀÏÂ÷) : 2023-05-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20988 ¼­¿ï 2024 Á¦ 13ȸ ´ëÇѺñ´¢»ý½Ä±âÅëÇÕ±â´ÉÀÇÇבּ¸È¸ Çмú´ëȸ : 2024-06-22 0 11 2024-06-14
20987 Ãæ³² 2024³â ´ëÇÑ°í°üÀýÇÐȸ Áø·áÁöħ ½ÉÆ÷Áö¿ò : 2024-06-22 0 10 2024-06-14
20986 ±¤ÁÖ Á¦24ȸ ´ëÇÑôÃ߽Űæ¿Ü°úÇÐȸ È£³²Áöȸ Á¤±âÇмú´ëȸ : 2024-06-22 0 15 2024-06-14
20985 °æ±â ´ëÇÑÁ¾¾ç³»°úÇÐȸ KSMO Annual Academy for young oncologists(2ÀÏÂ÷) : 2024-06-22 0 9 2024-06-14
20984 °æºÏ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦43Â÷ ÇÏ°è±¹Á¦Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-22 0 8 2024-06-14
20983 °æ³² 2024 ÁøÁÖ½ÃÀÇ»çȸ »ó¹Ý±â Àǻ翬¼ö±³À° : 2024-06-22 0 4 2024-06-14
20982 °æ±â °¡Å縯´ëÇб³ÀÇÁ¤ºÎ¼º¸ðº´¿ø Á¦ 8Â÷ °æ±âºÏºÎ °³¿øÀǸ¦ À§ÇÑ Çмú´ëȸ : 2024-06-22 0 5 2024-06-14
20981 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ½ÉÆ÷Áö¾ö : 2024-06-22 0 7 2024-06-14
20980 ¼­¿ï ´ëÇÑÈĵÎÀ½¼º¾ð¾îÀÇÇÐȸ 11ȸ °ø¿¬¹ß¼º ½ÉÆ÷Áö¾ö : 2024-06-22 0 5 2024-06-14
20979 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇѳëÀÎÀçÈ°ÀÇÇÐȸ ³ëÀÎÀçÈ°Àü¹®°¡ ½ÉÈ­°úÁ¤ : 2024-06-22 0 5 2024-06-14
20978 ÀüºÏ Á¦75Â÷ Çѱ¹ÃéÀå¿Ü°úÇÐȸ Çмú´ëȸ : 2024-06-22 0 5 2024-06-14
20977 Á¦ÁÖ ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ The 18th Annual Summer Conference on Endovascular Neurosurgical Therapy (ASCENT 2024) 2ÀÏÂ÷ : 2024-06-22 0 4 2024-06-14
20976 ±¤ÁÖ 2024³â »ó¹Ý±â ±¤ÁÖ±¤¿ª½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-22 0 12 2024-06-14
20975 ¼­¿ï 2024³â ´ëÇÑÀÇ·áÁ¤º¸ÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-21 0 4 2024-06-14
20974 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2024 SNUH Rare Disease Workshop : 2024-06-21 0 3 2024-06-14
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷